HOOK News and Press, HOOKIPA Pharma Inc. From 03/22/24

Best-in-class preliminary Phase 2 data for HB-200 in combination with pembrolizumab in patients with recurrent/metastatic HPV16+ head and neck cancers in the first line setting Expect updated Phase 2 data with additional patients in Q2 2024; Company will also provide pivotal trial design and ...

Weir Group plc ADR (WEGRY) is expected to report for Q4 2023 So-Young International Inc. (SY) is expected to report for quarter end 2023-12-31 Atara Biotherapeutics Inc. (ATRA) is expected to report $-0.61 for Q4 2023 Adyen NV ADR (ADYEY) is expected to report for Q4 2023 Five Bel...

2024-03-06 17:09:23 ET Summary Baker Brothers' 13F portfolio value decreased from $17.35B to $8.79B. The largest five stakes in the portfolio are Incyte, BeiGene, ACADIA Pharma, Madrigal Pharma, and Rhythm Pharma. New stakes include Cerevel Therapeutics, while stake disposals ...

NEW YORK and VIENNA, Austria, March 06, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that HOOKIPA’s Chief Financial Officer, Reinhar...

2024-01-29 10:43:48 ET More on HOOKIPA Pharma Hookipa Pharma stock soars on $21.25M equity investment from Gilead HOOKIPA Pharma GAAP EPS of -$0.17 beats by $0.03, revenue of $6.87M beats by $2.62M Seeking Alpha’s Quant Rating on HOOKIPA Pharma Histori...

HOOKIPA to prioritize clinical development of HB-200 for the treatment of HPV16+ head and neck cancers and Gilead-partnered programs in infectious disease HOOKIPA will regain global development rights to HB-700 program for KRAS-mutated cancers from Roche; HOOKIPA remains eligible for milest...

NEW YORK and VIENNA, Austria, Jan. 16, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced the appointment of Mark Winderlich, PhD, as Chief Devel...

2023-12-21 09:55:17 ET DENVER, Colo., Dec. 21, 2023 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual volume; HOOKIPA Pharma Inc (NASDAQ: HOOK), ParaZero Technologies Ltd (NASDAQ: PRZO), Atara Biotherapeutics Inc (NASDA...

2023-12-21 09:03:14 ET More on HOOKIPA Pharma HOOKIPA Pharma GAAP EPS of -$0.17 beats by $0.03, revenue of $6.87M beats by $2.62M Seeking Alpha’s Quant Rating on HOOKIPA Pharma Historical earnings data for HOOKIPA Pharma Financial information for HOOKI...

2023-12-21 08:50:38 ET DENVER, Colo., Dec 21, 2023 ( www.247marketnews.com )- HOOKIPA Pharma Inc. (NASDAQ: HOOK) reported, this morning, that Gilead Sciences, Inc. (NASDAQ: GILD) purchased 15 million shares of HOOKIPA’s common stock for approximately $21.25 million, at a price of...